Biospecifics Technologies Corp.: Form 8K - Filed by newsfilecorp.com

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 13, 2014

BIOSPECIFICS TECHNOLOGIES CORP.
(Exact name of registrant as specified in its charter)

Delaware 001-34236 11-3054851
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

35 Wilbur Street
Lynbrook, NY 11563
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: 516.593.7000

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))


Introductory Comment

     Throughout this Current Report on Form 8-K, the terms “we,” “us,” “our” and “Company” refer to BioSpecifics Technologies Corp.

Item 7.01 Regulation FD Disclosure

     The presentation materials, furnished as Exhibit 99.1 hereto and which are incorporated herein by reference, will be used by officers and other representatives of the Company in meetings with potential investors and stockholders during the month of November and will be used first on November 14, 2014.

Item 9.01 Financial Statements and Exhibits

(d)

Exhibits.


Exhibit No. Description
   
99.1 Presentation materials to be used by officers and other representatives of the Company


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 13, 2014

  BioSpecifics Technologies Corp.
     
  By: /s/ Thomas L. Wegman
    Name: Thomas L. Wegman
    Title: President


EXHIBIT INDEX

Exhibit
No.
Description
   
99.1 Presentation materials to be used by officers and representatives of the Company